Αρχική World News Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate... World News Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less Από Ogkologos - 5 Μαρτίου, 2026 429 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR SABR with Immunotherapy Significantly Improves Event-Free Survival in Patients with Newly... 27 Ιουλίου, 2023 Meeting Cancer Survivors’ Psychosocial Health Needs: A Conversation with Dr. Patricia... 7 Ιουνίου, 2022 More Immunotherapy Options Approved for Treating Endometrial Cancer 6 Αυγούστου, 2024 Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz 12 Νοεμβρίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Cholesterol Drug May Help Protect the Heart during Chemotherapy for Lymphoma Prevalence of ALK Alterations in Non-Small Cell Lung Cancer Determined Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... Adjuvant mRNA-4157 Plus Pembrolizumab Prolongs RFS versus Pembrolizumab Alone in Patients...